Summary
- Patients with obesity are seeking alternative therapies like compounded peptides despite potential risks and lack of clinical trials.
- Compounded peptides require specialized training, proper certification, and extensive testing for safety and efficacy.
- A checklist is provided for patients seeking compounded semaglutide or tirzepatide to ensure pharmacy legitimacy and quality.
- Challenges exist with some compounding pharmacies potentially skirting quality measures and falsifying records.
- Providers should prioritize patient care and safety while advocating for improved oversight and access to safe treatments for patients with obesity.
New guidelines have been released for patients seeking compounded medications to treat obesity, such as semaglutide or tirzepatide. Compounded medications are made by special pharmacies and are not regulated by the FDA in the same way as regular medications.
Patients are advised to check the accreditation of the pharmacy, ask for inspection reports, and ensure that the pharmacy follows good manufacturing practices. It is important to know where the medication comes from and to request a certificate of analysis to check for impurities.
While compounded medications may be a tempting alternative for some patients, there are risks involved, as not all pharmacies may adhere to proper quality measures. Patients are encouraged to ask questions and do their research before obtaining compounded medications.
The goal of these guidelines is to educate patients and help them make informed decisions about their healthcare. Providers are also urged to work towards improving the healthcare system to ensure that patients have access to safe and effective treatments for obesity.
Source link
Diabetes & Endocrinology, Pharmacists